Emily S. Wu

Emily S. Wu

Auto-generated profile, based on publicly available information

Emily S. Wu

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific St, Box 356460, Seattle, WA 98195, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
EWEmily S. Wu
Emily S. Wu
TOTitilope Oduyebo
Titilope Oduyebo
LCLauren P. Cobb
Lauren P. Cobb
DCDiana Cholakian
Diana Cholakian
XKXiangrong Kong
Xiangrong Kong
KRKara Long Roche
Kara Long Roche

1 October 2017 in Journal of Global Oncology
Verified
Journal Article
Open access
EWEmily S. Wu
Emily S. Wu
JJJose Jeronimo
Jose Jeronimo
SFSarah Feldman
Sarah Feldman
Cervical cancer is one of the most common cancers among women worldwide, and approximately 85% of new diagnoses occur in less-developed regions of the world. Global efforts in cervical cancer to date have focused on primary and secondary prevention strategies of human papillomavirus vaccination and cervical cancer screening. Cervical cancer screening is effective to reduce the incidence of cervical cancer and can result in diagnosis at earlier stages, but it will take time to realize its full impact. With expansion of screening programs, there is now a greater imperative to increase access to treatment for women who have cervical cancer, particularly in earlier stages of disease, when it is still curable. Resources for multimodality treatment can be limited—or even absent—in many less-developed regions of the world and may be associated with geographic, social, and financial barriers for the patient. However, there is evidence that, in many cases, less-invasive and less–resource-intensive treatment options are still effective. To this end, the National Comprehensive Cancer Network and American Society of Clinical Oncology have published guideline adaptations for specific resource constraints, and research about more conservative approaches to the treatment of cervical cancer continues. This review focuses on potential barriers and challenges to provision of safe and effective treatment of early-stage cervical cancer in lower-resource settings, and it suggests future directions for expansion of access to cervical cancer treatment around the world.

1 February 2020 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
EWEmily S. Wu
Emily S. Wu
RURenata R. Urban
Renata R. Urban
EKElizabeth M. Krantz
Elizabeth M. Krantz
NMNoleb M. Mugisha
Noleb M. Mugisha
CNCarolyn Nakisige
Carolyn Nakisige
CCCorey Casper
Corey Casper
Our objective was to determine how HIV infection impacts cervical cancer stage at presentation and overall survival (OS) among Ugandan women. This was a prospective study of 149 women diagnosed with cervical cancer from 2013 to 2015 at the Uganda Cancer Institute. Poisson regression models were fit to calculate prevalence ratios (PR) for the association between HIV infection and late stage at cancer diagnosis. The association between HIV infection and OS after cervical cancer diagnosis was evaluated using Cox proportional hazards models. The cohort included 53 HIV-positive and 96 HIV-negative participants. Median age at diagnosis was 44 years for HIV-positive and 54 years for HIV-negative participants. Seventy-seven percent of HIV-positive participants received antiretroviral therapy. Median baseline CD4 count was 373 cells/mm3 for HIV-positive participants versus 926 cells/mm3 for HIV-negative participants. Thirty-two percent of HIV-positive participants were diagnosed with late stage cervical cancer (III-IV) versus 39% of HIV-negative participants. No association was found between late stage at cancer diagnosis and HIV infection (PR adjusted for age, parity and transport cost 1.0, 95%CI 0.6-1.8). Most women presenting for care received cancer treatment, though almost half who received radiotherapy did not complete treatment. The median OS was 13.7 months for HIV-positive participants and 24.3 months for HIV-negative participants. After adjusting for age and stage, HIV infection was weakly associated with OS (HR 1.3, 95%CI 0.8-2.2). In Uganda, cervical cancer is often incompletely treated and survival remains poor. HIV infection was not associated with cervical cancer stage at diagnosis, but may be weakly associated with shorter survival.

1 August 2017 in Taiwanese Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
EWEmily S. Wu
Emily S. Wu
EAElaine T. Aguinaldo
Elaine T. Aguinaldo
YHYaser R. Hussein
Yaser R. Hussein
RSRudy S. Suidan
Rudy S. Suidan
DCDennis S. Chi
Dennis S. Chi